142374-17-2 Usage
Molecular weight
526.64 g/mol The molecular weight is the mass of one mole of the compound, calculated by adding the atomic weights of all the atoms in the molecular formula.
Appearance
White crystalline solid The appearance describes the physical form and color of the compound.
Solubility
Soluble in methanol and ethanol, slightly soluble in water The solubility describes the ability of the compound to dissolve in different solvents.
Melting point
160-162°C The melting point is the temperature at which the compound changes from a solid to a liquid state.
Stereochemistry
(S)-stereoisomer The stereochemistry describes the three-dimensional shape of the compound, with the (S)-stereoisomer indicating a specific arrangement of the atoms.
Functional groups
Ester, diazo, oxo, phenylmethoxy, carbonyl, amino, butyl, phenoxypropyl The functional groups are specific chemical groups within the compound that are responsible for its chemical reactivity and properties.
Uses
Research or pharmaceutical applications The uses describe the potential applications of the compound, such as in scientific research or in the development of pharmaceutical drugs.
Check Digit Verification of cas no
The CAS Registry Mumber 142374-17-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,2,3,7 and 4 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 142374-17:
(8*1)+(7*4)+(6*2)+(5*3)+(4*7)+(3*4)+(2*1)+(1*7)=112
112 % 10 = 2
So 142374-17-2 is a valid CAS Registry Number.
142374-17-2Relevant academic research and scientific papers
Non-Peptide Fibrinogen Receptor Antagonists. 2. Optimization of a Tyrosine Template as a Mimic for Arg-Gly-Asp
Egbertson, Melissa S.,Chang, Charles T.-C.,Duggan, Mark E.,Gould, Robert J.,Halczenko, Wasyl,et al.
, p. 2537 - 2551 (2007/10/02)
Inhibitors of platelet-fibrinogen binding offer an opportunity to interrupt the final, common pathway for platelet aggregation.Small molecule inhibitors of the platelet fibrinogen receptor GPIIb/IIIa were prepared and evaluated for their ability to prevent platelet aggregation.Compound 23m (L-700, 462/MK-383) inhibited in vitro platelet aggregation with an IC50 of 9 nM and demonstrated a selectivity of >24000-fold between platelet and human umbilical vein endothelial cell fibrinogen receptors.Dose-dependent inhibition of ex vivo platelet aggregation induced by ADP was achieved with iv infusions 0.1-10 μg/kg/min of 23m in anesthetized dogs, with 10 μg/kg/min completely inhibiting platelet aggregation during the entire 6 h infusion protocol.Platelet aggregatability returned rapidly after the termination of the 23m infusions.These features suggest that 23m may be useful in the treatment of arterial occlusive disorders.
